Tag: Non-ergot D2/D3-preferring dopamine agonist

  • Pramipexole

    Non-ergot D2/D3-preferring dopamine agonist

    A non-ergot benzothiazole D3-preferring dopamine receptor agonist; first-line for Parkinson disease and restless legs syndrome.

    Abstract

    Pramipexole ((6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine; CAS 104632-26-0; molecular formula C10H17N3S; molecular weight 211.32) is a non-ergot benzothiazole dopamine receptor agonist developed at Boehringer Ingelheim and approved by the FDA in 1997 under the trade name Mirapex. The compound is D3-preferring (D3 Ki approximately 0.5 nM, D2 Ki approximately 4 nM, ratio approximately 8) with minimal activity at non-dopaminergic receptors, distinguishing it from ergoline agonists by absence of the rare cardiac valvulopathy and serosal fibrosis associated with the ergot agonists. Plasma half-life is 8 to 12 hours; metabolism is minimal (90 percent renal excretion unchanged). Approved for Parkinson disease, restless legs syndrome. The dopaminergic activity produces a recognized risk of impulse control disorders (pathological gambling, hypersexuality) in approximately 14 percent of long-term users.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.